Poland· PL-100027929
Vectibix
A panitumumab product containing panitumumabum, registered in Poland by Amgen Europe B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Panitumumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FE02 (panitumumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Panitumumab · ATC L01FE02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Panitumumabum
- Manufacturer
- Amgen Europe B.V.
- Country
- Poland (PL)
- ATC code
- L01FE02
- ATC class
- Panitumumab
- Defined daily dose
- 30 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909990646531
- gtin05909990646548
- gtin05909990646555
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
27 interactions on record for panitumumab.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Panitumumab · interactions on record
27 records
- 14 severe
- 13 moderate
Most severe, free to view
- AmiodaroneC01BD01severe
- DofetilideC01BD04severe
- DronedaroneC01BD07severe
- IrinotecanL01CE02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Panitumumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVectibix 20 mg/mlAmgen Europe
- CzechiaVECTIBIXAmgen Europe B.V., Breda
- FinlandVectibixParanova Oy
- IrelandVectibix 20 mg/mL concentrate for solution for infusionAmgen Europe B.V.,
- IcelandVectibixAmgen Europe B.V.*
- NorwayVectibixAmgen Europe B.V.
- SwedenVectibix 20 mg/ml Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- United StatesVectibixAmgen, Inc
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vectibix
- Norway · Vectibix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/39768e58-a01e-4d5e-bb66-ef79159ebc42 GET /v1/drugs/39768e58-a01e-4d5e-bb66-ef79159ebc42?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "20 mg/ml",
"packaging": "05909990646531 ¦ Rpz ¦ EU/1/07/423/001 ¦ 43489\n1 fiol. 5 ml\n05909990646548 ¦ Rpz ¦ Skasowane ¦ EU/1/07/423/002 ¦ 43491\n1 fiol. 10 ml\n05909990646555 ¦ Rpz ¦ EU/1/07/423/003 ¦ 43492\n1 fiol. 20 ml",
"substance": "Panitumumabum 20 mg/ml",
"common_name": "Panitumumabum",
"pl_product_id": "100027929",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about panitumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.